Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
NEW YORK, Feb. 18, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 25, 2016, to discuss financial results for the fourth quarter and year ended December, 31, 2015, and provide a business update.
To access the live conference call via phone, dial 1-844-835-6563. The International dial-in number is 1-970-315-3916. The conference ID number for the live call is 45850524.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
CONTACT: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
